DJIA 17,111.91 5.21 0.03%
NASDAQ 4,569.36 -1.28 -0.03%
S&P 500 1,998.98 -1.04 -0.05%
market minute promo

PTC Therapeutics, Inc. (NASDAQ: PTCT)

31.84 -0.49 (-1.52%)

Quote as of


company name or ticker

Recent Quotes

PTCT $31.84 -1.52%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $32.45
Previous Close $32.33
Daily Range $31.18 - $33.33
52-Week Range $13.15 - $34.65
Market Cap $957.4M
P/E Ratio 1.21
Dividend (Yield) $0.00 (0.0%)
Volume 182,855
Average Daily Volume 260,755
Current FY EPS -$3.56

Sector

Industry

PTC Therapeutics, Inc. (PTCT) Description

PTC Therapeutics, Inc. Website: http://www.ptcbio.com/

News & Commentary Rss Feed

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q2 2014 Results - Earnings Call Transcript

PTC Therapeutics: A Speculative Buy On Rare Disease Portfolio And Potential Takeover Target

Down 17%: Is Sarepta a Bad News Buy?

Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.

Sector Update: Healthcare Shares Flat Pre-Market

Sector Update: Healthcare

PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients

PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients With Nonsense Mutation Cystic Fibrosis (nmCF)

Cramer's Lightning Round - The Street Is Addicted To Qualcomm (6/9/14)

Why Wall Street is Betting Heavily Against Sarepta Therapeutics

Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.

Why PTC Therapeutics Inc. Shares Took Off

PTC shares soar after receiving positive comments from Credit Suisse. However, here's what shareholders should really be focused on.

See More PTCT News...